Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Download PDF
Semin Thromb Hemost
DOI: 10.1055/a-2778-9989
DOI: 10.1055/a-2778-9989
Review Article
Von Willebrand Disease Type 2A: An Update
Authors
Funding Information This work was partially supported by the Italian Ministry of Health (Bando Ricerca Corrente). The Hemostasis & Thrombosis Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico is member of the European Reference Network on Rare Haematological Diseases EuroBloodNet-Project ID No. 101157011. ERN-EuroBloodNet is partly co-funded by the European Union within the framework of the Fourth EU Health Programme. The Department of Pathophysiology and Transplantation, University of Milan, is funded by the Italian Ministry of Education and Research (MUR): Dipartimenti di Eccellenza Program 2023 to 2027.
Abstract
Dysfunctional or quantitatively deficient von Willebrand factor (VWF) underlies von Willebrand disease (VWD), the most common inherited bleeding disorder. Type 2A VWD is a qualitative defect marked by impaired VWF-dependent platelet adhesion, typically reflected in disproportionately reduced ratios of platelet-dependent VWF activity to antigen (VWF activity/VWF:Ag) and collagen binding to antigen (VWF:CB/VWF:Ag). This phenotype results from a selective reduction or lack of high- and intermediate-molecular-weight multimers, which are essential for effective hemostasis under high shear stress. The lack of multimer arises from impaired multimer assembly and/or increased proteolytic cleavage of VWF by ADAMTS13. Clinically, type 2A tends to present with greater severity than other type 2 variants, manifesting as mucocutaneous bleeding, often including heavy menstrual bleeding, epistaxis, post-surgical bleeding and gastrointestinal hemorrhage from angiodysplasia. Diagnosis relies on functional assays and VWF multimer analysis, supported by genetic testing that identifies subtype-specific mutations affecting VWF multimeric structure and therefore its function. Type 2A is typically inherited in an autosomal dominant manner, with rare exceptions of autosomal recessive inheritance. Structural and molecular studies are continuing to elucidate how domain-specific variants disrupt multimeric structure and thus interactions with its ligands. Management is guided by bleeding severity and includes desmopressin (following responsiveness testing) and VWF replacement therapy. This review provides an in-depth update on type 2A VWD, covering its epidemiology, pathophysiology across distinct subtypes, clinical manifestations, diagnostic approach, molecular and structural insights, and current therapeutic strategies.
Contributors' Statement
O.S.: conceptualization, methodology, visualization, writing—original draft, writing—review & editing; L.B.: writing—review & editing; P.M.M.: writing—review & editing; F.P.: writing—review & editing.
Publication History
Received: 16 October 2025
Accepted: 23 December 2025
Accepted Manuscript online:
26 December 2025
Article published online:
08 January 2026
© 2026. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Springer TA. Biology and physics of von Willebrand factor concatamers. J Thromb Haemost 2011; 9 (0 1): 130-143
- 2 Ruggeri ZM. Structure and function of von Willebrand factor. Thromb Haemost 1999; 82 (02) 576-584
- 3 Sadler JE, Budde U, Eikenboom JC. et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4 (10) 2103-2114
- 4 Seidizadeh O, Eikenboom JCJ, Denis CV. et al. von Willebrand disease. Nat Rev Dis Primers 2024; 10 (01) 51
- 5 Zhou YF, Eng ET, Zhu J, Lu C, Walz T, Springer TA. Sequence and structure relationships within von Willebrand factor. Blood 2012; 120 (02) 449-458
- 6 Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 2015; 125 (13) 2019-2028
- 7 Wise RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell 1988; 52 (02) 229-236
- 8 Rosenberg JB, Haberichter SL, Jozwiak MA. et al. The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF. Blood 2002; 100 (05) 1699-1706
- 9 Petri A, Kim HJ, Xu Y. et al. Crystal structure and substrate-induced activation of ADAMTS13. Nat Commun 2019; 10 (01) 3781
- 10 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69 (02) 454-459
- 11 Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost 2010; 8 (01) 213-216
- 12 Seidizadeh O, Baronciani L, Pagliari MT. et al. Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2. Blood Adv 2022; 6 (13) 4031-4040
- 13 Veyradier A, Boisseau P, Fressinaud E. et al; French Reference Center for von Willebrand disease. A laboratory phenotype/genotype correlation of 1167 French patients from 670 families with von Willebrand disease: a new epidemiologic picture. Medicine (Baltimore) 2016; 95 (11) e3038
- 14 de Wee EM, Leebeek FW, Eikenboom JC. Diagnosis and management of von Willebrand disease in The Netherlands. Semin Thromb Hemost 2011; 37 (05) 480-487
- 15 Yadegari H, Halimeh S, Krahforst A. et al. Landscape and spectrum of VWF variants in type 2 von Willebrand disease: insights from a German patient cohort. Thromb Haemost 2025; Epub ahead of print
- 16 Borràs N, Batlle J, Pérez-Rodríguez A. et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. Haematologica 2017; 102 (12) 2005-2014
- 17 DiGiandomenico S, Christopherson PA, Haberichter SL, Abshire TC, Montgomery RR, Flood VH. Zimmerman Program Investigators. Laboratory variability in the diagnosis of type 2 VWD variants. J Thromb Haemost 2021; 19 (01) 131-138
- 18 Seidizadeh O, Cairo A, Baronciani L, Valenti L, Peyvandi F. Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases. NPJ Genom Med 2023; 8 (01) 31
- 19 Seidizadeh O, Cairo A, Oriani C, Peyvandi F. Global prevalence and ethnic diversity of von Willebrand disease: an updated population-based genetic analysis. 2025. Preprint ] (2025).
- 20 Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost 2006; 32 (05) 514-521
- 21 Saadalla A, Seheult J, Pruthi RK, Chen D. Von Willebrand factor multimer analysis and classification: a comprehensive review and updates. Semin Thromb Hemost 2023; 49 (06) 580-591
- 22 James PD, Connell NT, Ameer B. et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv 2021; 5 (01) 280-300
- 23 Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest 1986; 77 (03) 947-951
- 24 Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A 1990; 87 (16) 6306-6310
- 25 Hassenpflug WA, Budde U, Obser T. et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood 2006; 107 (06) 2339-2345
- 26 Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267 (07) 4424-4430
- 27 Sutherland JJ, O'Brien LA, Lillicrap D, Weaver DF. Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model 2004; 10 (04) 259-270
- 28 Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood 2012; 119 (19) 4543-4553
- 29 Schneppenheim R, Michiels JJ, Obser T. et al. A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE. Blood 2010; 115 (23) 4894-4901
- 30 Pagliari MT, Baronciani L, Garcìa Oya I. et al. A synonymous (c.3390C>T) or a splice-site (c.3380-2A>G) mutation causes exon 26 skipping in four patients with von Willebrand disease (2A/IIE). J Thromb Haemost 2013; 11 (07) 1251-1259
- 31 Gaucher C, Diéval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 1994; 84 (04) 1024-1030
- 32 Schneppenheim R, Thomas KB, Krey S. et al. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum Genet 1995; 95 (06) 681-686
- 33 Ruggeri ZM, Nilsson IM, Lombardi R, Holmberg L, Zimmerman TS. Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC). J Clin Invest 1982; 70 (05) 1124-1127
- 34 Enayat MS, Ravanbod S, Rassoulzadegan M. et al. Identification of a homozygous Cys410Ser mutation in the von Willebrand factor D2 domain causing type 2A(IIC) von Willebrand disease phenotype in an Iranian patient. Haemophilia 2013; 19 (04) e261-e264
- 35 Brehm MA, Huck V, Aponte-Santamaría C. et al. von Willebrand disease type 2A phenotypes IIC, IID and IIE: a day in the life of shear-stressed mutant von Willebrand factor. Thromb Haemost 2014; 112 (01) 96-108
- 36 Schneppenheim R, Brassard J, Krey S. et al. Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease. Proc Natl Acad Sci U S A 1996; 93 (08) 3581-3586
- 37 Kinoshita S, Harrison J, Lazerson J, Abildgaard CF. A new variant of dominant type II von Willebrand's disease with aberrant multimeric pattern of factor VIII-related antigen (type IID). Blood 1984; 63 (06) 1369-1371
- 38 Tjernberg P, Vos HL, Spaargaren-van Riel CC. et al. Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease. Thromb Haemost 2006; 96 (06) 717-724
- 39 Enayat MS, Guilliatt AM, Surdhar GK. et al. Aberrant dimerization of von Willebrand factor as the result of mutations in the carboxy-terminal region: identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease. Blood 2001; 98 (03) 674-680
- 40 Tjernberg P, Vos HL, Castaman G, Bertina RM, Eikenboom JC. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost 2004; 2 (02) 257-265
- 41 Tischer A, Machha VR, Frontroth JP. et al. Enhanced local disorder in a clinically elusive von Willebrand factor provokes high-affinity platelet clumping. J Mol Biol 2017; 429 (14) 2161-2177
- 42 Sanders YV, Groeneveld D, Meijer K. et al; WiN study group. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood 2015; 125 (19) 3006-3013
- 43 Seidizadeh O, Baronciani L, Pagliari MT. et al. Genetic determinants of enhanced von Willebrand factor clearance from plasma. J Thromb Haemost 2023; 21 (05) 1112-1122
- 44 Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci U S A 1995; 92 (07) 2428-2432
- 45 Seidizadeh O, Mollica L, Giana D. et al. Deep molecular modeling and mechanistic insights into type 2A VWD with VWF A2 domain mutations. Res Pract Thromb Haemost 2025; 9 (07) 103233
- 46 Casonato A, Cattini MG, Daidone V, Pontara E, Bertomoro A, Prandoni P. Diagnostic value of measuring platelet von Willebrand factor in von Willebrand disease. PLoS One 2016; 11 (08) e0161310
- 47 Xu AJ, Springer TA. Mechanisms by which von Willebrand disease mutations destabilize the A2 domain. J Biol Chem 2013; 288 (09) 6317-6324
- 48 Interlandi G, Ling M, Tu AY, Chung DW, Thomas WE. Structural basis of type 2A von Willebrand disease investigated by molecular dynamics simulations and experiments. PLoS One 2012; 7 (10) e45207
- 49 Lynch CJ, Cawte AD, Millar CM, Rueda D, Lane DA. A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct. PLoS One 2017; 12 (11) e0188405
- 50 Zhang Q, Zhou YF, Zhang CZ, Zhang X, Lu C, Springer TA. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci U S A 2009; 106 (23) 9226-9231
- 51 Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118 (12) 3212-3221
- 52 Wu T, Lin J, Cruz MA, Dong JF, Zhu C. Force-induced cleavage of single VWFA1A2A3 tridomains by ADAMTS-13. Blood 2010; 115 (02) 370-378
- 53 Fang X, Lin J, Fang Y, Wu J. Prediction of spacer-α6 complex: a novel insight into binding of ADAMTS13 with A2 domain of von Willebrand factor under forces. Sci Rep 2018; 8 (01) 5791
- 54 Castaman G, Federici AB, Tosetto A. et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012; 10 (04) 632-638
- 55 Woods AI, Paiva J, Primrose DM, Blanco AN, Sánchez-Luceros A. Type 2A and 2M von Willebrand disease: differences in phenotypic parameters according to the affected domain by disease-causing variants and assessment of pathophysiological mechanisms. Semin Thromb Hemost 2021; 47 (07) 862-874
- 56 de Wee EM, Sanders YV, Mauser-Bunschoten EP. et al; WiN study group. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost 2012; 108 (04) 683-692
- 57 Seidizadeh O, Ciavarella A, Baronciani L. et al. Genetic determinants of clinical variability in type 2 von Willebrand disease: bridging genotype and phenotype. Haematologica 2025; Epub ahead of print
- 58 Biguzzi E, Siboni SM, Peyvandi F. How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease. Blood 2020; 136 (10) 1125-1133
- 59 Chornenki NLJ, Ocran E, James PD. Special considerations in GI bleeding in VWD patients. Hematology (Am Soc Hematol Educ Program) 2022; 2022 (01) 624-630
- 60 Crossette-Thambiah C, Randi AM, Laffan M. von Willebrand disease and angiodysplasia: a wider view of pathogenesis in pursuit of therapy. Haematologica 2025; 110 (03) 588-595
- 61 Baronciani L, Federici AB, Punzo M. et al. Type 2A (IIH) von Willebrand disease is due to mutations that affect von Willebrand factor multimerization. J Thromb Haemost 2009; 7 (07) 1114-1122
- 62 Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J. von Willebrand factor Subcommittee of the Standardization and Scientific Committee of the International Society for Thrombosis and Haemostasis. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (07) 1345-1350
- 63 Seidizadeh O, Baronciani L, Lillicrap D, Peyvandi F. Application of genetic testing for the diagnosis of von Willebrand disease. J Thromb Haemost 2024; 22 (08) 2115-2128
- 64 de Jong A, Eikenboom J. Von Willebrand disease mutation spectrum and associated mutation mechanisms. Thromb Res 2017; 159: 65-75
- 65 Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24 (03) 123-134
- 66 White-Adams TC, Ng CJ, Jacobi PM, Haberichter SL, Di Paola JA. Mutations in the D'D3 region of VWF traditionally associated with type 1 VWD lead to quantitative and qualitative deficiencies of VWF. Thromb Res 2016; 145: 112-118
- 67 Seidizadeh O, Baronciani L, Peyvandi F. Challenges and considerations of genetic testing in von Willebrand disease. Res Pract Thromb Haemost 2025; 9 (01) 102686
- 68 Favaloro EJ. Genetic testing for von Willebrand disease: the case against. J Thromb Haemost 2010; 8 (01) 6-12
- 69 Favaloro EJ, Pasalic L, Curnow J. Type 2M and type 2A von Willebrand disease: similar but different. Semin Thromb Hemost 2016; 42 (05) 483-497
- 70 Seidizadeh O, Mollica L, Zambarbieri S. et al. Type 2M/2A von Willebrand disease: a shared phenotype between type 2M and 2A. Blood Adv 2024; 8 (07) 1725-1736
- 71 Favaloro EJ, Bonar RA, Mohammed S. et al. Type 2M von Willebrand disease—more often misidentified than correctly identified. Haemophilia 2016; 22 (03) e145-e155
- 72 Favaloro EJ, Mohammed S, Vong R. et al. How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types. Haemophilia 2021; 27 (01) 137-148
- 73 Connell NT, Flood VH, Brignardello-Petersen R. et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021; 5 (01) 301-325
- 74 Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351 (07) 683-694
- 75 Laan S, Del Castillo Alferez J, Cannegieter S. et al. DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis. Blood 2025; 145 (16) 1814-1825
- 76 Federici AB, Mazurier C, Berntorp E. et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103 (06) 2032-2038
- 77 Atiq F, Heijdra J, Snijders F. et al. Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease. Blood Adv 2022; 6 (18) 5317-5326
- 78 Rauch A, Paris C, Repesse Y. et al; French Reference Center on von Willebrand Disease. Gastrointestinal bleeding from angiodysplasia in von Willebrand disease: improved diagnosis and outcome prediction using videocapsule on top of conventional endoscopy. J Thromb Haemost 2021; 19 (02) 380-386
- 79 Roberts JC, Escobar MA, Acharya S. et al. Retrospective chart review of GI bleeding in people with von Willebrand disease. Haemophilia 2024; 30 (04) 970-980
- 80 Brown R. Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case report. Blood Coagul Fibrinolysis 2017; 28 (07) 570-575
- 81 Gill JC, Castaman G, Windyga J. et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood 2015; 126 (17) 2038-2046
- 82 Franchini M, Seidizadeh O, Mannucci PM. Prophylactic management of patients with von Willebrand disease. Ther Adv Hematol 2021; 12: 20 406207211064064
- 83 Jiang D, Wang M, Wheeler AP, Croteau SE. 2025 clinical trials update on hemophilia, VWD, and rare inherited bleeding disorders. Am J Hematol 2025; 100 (04) 666-684
- 84 de Jong A, Dirven RJ, Boender J. et al. Ex vivo improvement of a von Willebrand disease type 2A phenotype using an allele-specific small-interfering RNA. Thromb Haemost 2020; 120 (11) 1569-1579
- 85 Lenting PJ, Kizlik-Manson C, Casari C. Towards novel treatment options in von Willebrand disease. Haemophilia 2022; 28 (Suppl. 04) 5-10